Compare SER & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | NEPH |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4M | 49.4M |
| IPO Year | 2024 | 2004 |
| Metric | SER | NEPH |
|---|---|---|
| Price | $2.11 | $4.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $6.00 |
| AVG Volume (30 Days) | ★ 53.1K | 17.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | $130,000.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $35.25 |
| Revenue Growth | ★ 132.14 | 32.67 |
| 52 Week Low | $1.22 | $2.66 |
| 52 Week High | $5.83 | $6.42 |
| Indicator | SER | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 50.17 |
| Support Level | $1.69 | $4.00 |
| Resistance Level | $2.29 | $4.26 |
| Average True Range (ATR) | 0.23 | 0.26 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 11.54 | 27.96 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.